All Publications
5 min read

Criteo Completes Cross-Border Conversion to Luxembourg and Announces U.S. Redomiciliation: A Two-Stage Restructuring to Become a Delaware Corporation | ULF New York

M&A Monitoring

Criteo Completes Cross-Border Conversion to Luxembourg and Announces U.S. Redomiciliation: A Two-Stage Restructuring to Become a Delaware Corporation

Criteo S.A. completed a cross-border conversion from France to Luxembourg on July 29, 2026, terminating its ADS program and listing ordinary shares directly on Nasdaq under 'CRTO.' The board has simultaneously approved a second cross-border merger to redomicile from Luxembourg to the United States, subject to shareholder approval, with closing expected in January 2027 and a planned transfer from Nasdaq to NYSE.

5 min read

Transaction Overview

Company: Criteo S.A. (now Criteo S.A., Luxembourg)
Sector: Digital advertising, commerce data, and artificial intelligence
Stage 1 (Completed July 29, 2026): Cross-border conversion from France to Luxembourg; ADS program terminated; ordinary shares listed directly on Nasdaq as "CRTO"
Stage 2 (Announced): Cross-border merger from Luxembourg to the United States (wholly owned U.S. subsidiary); subject to shareholder approval
Expected Stage 2 Closing: January 2027
Planned Exchange Transfer: Nasdaq to NYSE

Stage 1: France to Luxembourg Conversion

Legal Mechanism

The cross-border conversion from France to Luxembourg was effected under EU Directive 2019/2121 (the Cross-Border Conversions Directive), which provides a harmonized legal framework for companies to convert their legal form and registered office from one EU member state to another while maintaining legal continuity — the company retains its legal identity, contracts, assets, and liabilities.

Key features of the completed conversion:

Legal continuity: Criteo's contracts, intellectual property registrations, employment agreements, and other legal relationships continue in force without novation or assignment. The company is the same legal entity; only its governing law and registered office have changed.

ADS termination: Criteo previously listed on Nasdaq through American Depositary Shares (ADS), each representing one ordinary share. The ADS structure was used because French corporate law and Nasdaq listing requirements created friction for direct listing of French shares. Under Luxembourg law, this friction is reduced, allowing direct listing of ordinary shares. Each ADS was exchanged for one ordinary share at termination.

Governing law change: Criteo is now governed by Luxembourg company law (the loi du 10 août 1915 concernant les sociétés commerciales, as amended) rather than French company law (the Code de commerce). Luxembourg company law is generally considered more flexible for capital market transactions, including share buybacks, capital reductions, and dividend distributions.

Implications for Shareholders

Shareholder rights: Luxembourg company law provides different shareholder rights than French law. Key differences include voting procedures, minority shareholder protections, and the rules governing extraordinary general meetings. Shareholders should review the updated articles of association.

Tax treatment: The conversion may have tax implications for shareholders depending on their jurisdiction of residence. Shareholders should consult their tax advisors.

Stage 2: Luxembourg to United States Redomiciliation

Legal Mechanism

The second stage — redomiciliation from Luxembourg to the United States — will be effected through a cross-border merger in which Criteo merges into its wholly owned U.S. subsidiary. Following the merger, the U.S. subsidiary will be the surviving entity and will be governed by U.S. (Delaware) corporate law.

This structure is commonly used for European companies seeking to redomicile to the United States because it avoids the need for a direct cross-border conversion (which is not available between EU and non-EU jurisdictions under current law) and instead uses the merger mechanism.

Shareholder Approval

The cross-border merger requires approval from Criteo's shareholders at an extraordinary general meeting. The proxy statement must include:

Merger terms: The exchange ratio (Criteo Luxembourg shares to Criteo U.S. shares), the treatment of outstanding equity awards, and the terms of the surviving entity's charter documents.

Fairness analysis: The board must demonstrate that the merger terms are fair to shareholders. A fairness opinion from an independent financial advisor is standard practice.

Tax analysis: The merger may be a taxable event for shareholders in some jurisdictions. The proxy statement must include a comprehensive tax disclosure.

Delaware Corporate Law

Following the redomiciliation, Criteo will be governed by Delaware General Corporation Law (DGCL). Key features of Delaware corporate law relevant to Criteo's stated objectives include:

Share buybacks: Delaware law provides significant flexibility for share repurchases, subject only to the solvency test (the company must be able to pay its debts as they come due). This is more permissive than Luxembourg law, which imposes additional restrictions on capital reductions.

Index eligibility: Many U.S. equity indices require constituent companies to be incorporated in the United States. Redomiciliation to Delaware may make Criteo eligible for inclusion in indices from which it was previously excluded as a foreign private issuer.

NYSE listing: Criteo plans to transfer its listing from Nasdaq to NYSE following the redomiciliation. NYSE listing requirements and the transfer process must be managed in parallel with the merger.

Employee Representation

French and Luxembourg corporate law require employee representation on the supervisory board (conseil de surveillance) or board of directors for companies above certain size thresholds. Delaware corporate law does not require employee representation. The redomiciliation will eliminate Criteo's employee representation obligations, which may require consultation with employee representatives before the merger is approved.

Ongoing Contracts and Data Protection

Existing contracts: Criteo's contracts are governed by various laws depending on the jurisdiction of the counterparty. The cross-border merger maintains legal continuity, so existing contracts continue in force. However, contracts that specify the governing law as French or Luxembourg law may need to be reviewed.

Data protection: Criteo processes large volumes of personal data as part of its digital advertising business. As a Luxembourg company, Criteo is subject to the GDPR under the jurisdiction of the Luxembourg data protection authority (CNPD). Following redomiciliation to the United States, Criteo's GDPR compliance framework must be reviewed to ensure continued compliance with EU data protection requirements for its European operations.

Strategic Rationale

Criteo's two-stage restructuring reflects a strategic decision to align its corporate domicile with its primary capital market (the United States) and its primary investor base (U.S. institutional investors). The elimination of the ADS structure reduces administrative complexity and cost. The redomiciliation to Delaware is intended to improve index eligibility, simplify capital market transactions, and align Criteo's governance with U.S. investor expectations.

This article is based on publicly available announcements. It does not constitute legal or investment advice.

Explore Topics

#Criteo#Redomiciliation#Cross-Border Merger#Luxembourg#France#Delaware#Nasdaq#NYSE#Corporate Restructuring#ADS#Digital Advertising

Share this article

X
ULF New York Bülteni

ABD Hukuk Rehberlerini
Doğrudan Alın

E-posta adresiniz yalnızca ULF New York hukuki içerikleri için kullanılır. İstediğiniz zaman aboneliğinizi iptal edebilirsiniz.

Related analysis and guides

Further Reading

M&A Monitoring3 min read

Supernus and Indivior Announce All-Stock Merger to Create Integrated CNS and Addiction Treatment Platform

Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into a definitive all-stock merger agreement to combine their neurology, psychiatry, and addiction treatment portfolios under a single commercial platform. Indivior shareholders will receive a $1 billion special cash dividend prior to closing, with the combined company retaining the Supernus name and trading on Nasdaq under 'SUPN.'

Read article
M&A Monitoring5 min read

Synlogic and Caldera Therapeutics Announce All-Stock Merger with $278 Million PIPE: A Reverse Merger That Takes Caldera Public Through Synlogic's Listed Shell

Synlogic Inc. and private company Caldera Therapeutics Inc. have announced an all-stock merger in which both companies will become subsidiaries of a newly formed holding company, to be named Caldera Therapeutics and listed on Nasdaq under 'CALD.' Simultaneously, the transaction includes approximately $278 million in PIPE financing. Economically, the transaction is a reverse merger: private Caldera uses Synlogic's public company infrastructure to access the capital markets.

Read article
M&A Monitoring6 min read

Wynnchurch Capital to Take Luxfer Holdings Private for Approximately $463 Million: Advanced Materials Manufacturer Exits NYSE After Definitive Agreement

Wynnchurch Capital has signed a definitive agreement to acquire Luxfer Holdings PLC for approximately $462.7 million at $17.37 per share, taking the NYSE-listed advanced materials manufacturer private. The transaction will be implemented via a UK court-sanctioned scheme of arrangement, with closing expected before year-end 2026.

Read article
M&A Monitoring7 min read

NextCure and Avere Therapeutics Announce Reverse Merger with $320 Million PIPE: Oral IL-23 Inhibitor AVR-001 Heads to Phase 3

Nasdaq-listed NextCure and private biotech Avere Therapeutics announced an all-stock merger structured as a tax-free reorganization under IRC §368(a), accompanied by approximately $320 million in concurrent PIPE financing. Avere shareholders and PIPE investors will hold approximately 98–99% of the combined company; existing NextCure shareholders receive approximately 1–2% plus a CVR tied to 90% of net proceeds from NextCure's legacy oncology assets. The combined company will trade as AVRX and advance AVR-001, a once-weekly oral IL-23 inhibitor licensed from Hansoh Pharmaceutical, through Phase 2b in psoriasis and Phase 2b in ulcerative colitis.

Read article

Published

Wednesday, July 29, 2026

Back to Publications